Over the next five years, the study will screen more than two million individuals, integrating gut microbiome, metabolomics, lipidomics, proteomics, exposomics, and wearable biosensor data to deliver ...

Technology advancement: The Company’s investigational ARC-IM ® and ARC-BCI ® platforms reached new milestones with the 4 th and 5 th successful BCI implants to restore thought-driven movement, and the ...

Dr. Tal Yossefi, a graduate of the University of Pennsylvania, and Dr. Elad Yossefi, who earned his degree from NYU and the ...

Finnish-Australian health technology company Agora, founded by Elizabeth Angel and Dr Olivia Lesslar, has officially launched ...

The Offering is being conducted on a firm commitment basis. Joseph Stone Capital, LLC is acting as sole underwriter for the Offering (the “Underwriter”). Sichenzia Ross Ference Carmel LLP is acting as ...

On April 29, 2025, Vivoryon disclosed preclinical data from a series of experiments in a chronic kidney disease animal model, analyzing different treatment regimens of varoglutamstat in combination ...

The Company Recently Announced Successful Topline Results from its Phase 3 SHIELD II Trial; D-PLEX₁₀₀ Demonstrated a Statistically Significant Reduction in Surgical Site Infections (“SSIs”) and ...

The Association of American Physicians and Surgeons (AAPS) filed its amicus brief in the U.S. Supreme Court on June 12 against a Colorado ban on conversion therapy for minors, in Chiles v. Salazar (No ...

All of the above-described awards were granted as an inducement material to each employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635 (c) (4). The options have a ...

It’s a reckoning and an opportunity to restore public trust in health innovation by delivering life-saving tools to the people who need them most with all of that information on our website.” ...

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement ...

NEW HAVEN, Conn., June 16, 2025 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote ...